Core Viewpoint - Hansen Pharmaceutical (002412.SZ) is currently in the process of scaling up the research for its new traditional Chinese medicine product, Cangrong Granules, which is in the stage of pilot testing [1] Group 1 - The company is focusing on research and development in the field of traditional Chinese medicine [1] - Cangrong Granules is a new drug under development by the company [1] - The current phase of research involves pilot testing for process scaling [1]

Core Viewpoint - Hansen Pharmaceutical (002412) is currently in the process of scaling up the production technology for its new traditional Chinese medicine product, Cangrong Granules, which is in the pilot study phase [1] Group 1 - The company is actively engaged in product research and development [1] - Cangrong Granules is a new drug derived from traditional Chinese medicine [1] - The product is currently undergoing process pilot testing [1]

Group 1 - The company has been asked about the proportion of innovative drugs in its R&D plans for the year [2] - The company stated that its traditional Chinese medicine new drug, Cangrong Granules, is currently in the process of pilot-scale research [2] - Further details regarding the company's R&D plans will be available in the 2024 annual report [2]

Group 1 - The company is currently in the process of scaling up the production of its new traditional Chinese medicine product, Cangrong Granules, which is in the pilot testing phase [1] - The Tianma Xingnao Capsule is designed to nourish the liver and kidneys, alleviate pain, and is used for symptoms related to liver and kidney deficiency, such as headaches, dizziness, memory decline, insomnia, sluggishness, tinnitus, and lower back pain [1] - For detailed information, the company refers investors to its 2024 annual report [1]